Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan dose-finding study in older adolescents and adults with osteogenesis imperfecta
NL-OMON61709Phase 2Not yet recruiting
- Sponsor
- Istituto Ortopedico Rizzoli
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of losartan in osteogenesis imperfecta (OI), sponsored by Istituto Ortopedico Rizzoli. Primary endpoint: Percentage change in CTX from baseline to week 24. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
losartan
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NL-OMON61709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61709.